Video Programs

Explore the latest trials on eltrombopag and elritercept, promising new treatments for low-risk MDS and CMML with TET2 mutations.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, enhancing treatment strategies.

A recent study highlights the benefits of early luspatercept treatment for patients with hemoglobin above 8, improving outcomes before transfusion dependency.

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and real-world evidence supporting its use.

A recent analysis reveals that low-risk MDS patients with earlier-stage profiles respond better to luspatercept, suggesting earlier treatment benefits.

A recent study explores inflammatory profiles in low-risk MDS, revealing distinct patient categories and implications for treatment strategies.

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment strategies.

Explore the clinical considerations for choosing between ESAs and luspatercept in treating low-risk MDS, focusing on efficacy and patient convenience.

Explore the advantages and challenges of long-term red blood cell transfusions for low-risk MDS patients, focusing on quality of life and treatment options.

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality of life.

Discover how a metal statin offers a promising backup treatment for MDS patients, enhancing transfusion outcomes while requiring careful monitoring.

Luspatercept emerges as a preferred treatment for low-risk MDS, enhancing hemoglobin levels and quality of life, even in diverse patient subgroups.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications like iron overload.

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies.

Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.

Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.

Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).

Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.

Panelists discuss how real-world practice blends evidence-based guidance with individualized adjustments for high-risk EGFR-mutant non–small-cell lung cancer (NSCLC) cases.

Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.

Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.

Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.

Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of personalized melanoma treatment.

Panelists discuss real-world data comparing outcomes of different immunotherapy combinations for advanced melanoma.